<DOC>
	<DOCNO>NCT00000754</DOCNO>
	<brief_summary>To determine safety efficacy two dos interferon alfa-2a ( IFN alfa-2a ) combination zidovudine ( AZT ) /zalcitabine ( ddC ) versus AZT/ddC patient HIV infection CD4 count &lt; 400 cells/mm3 . AZT ddC inhibit HIV act reverse transcriptase chain terminator , IFN alfa-2a inhibits translation viral protein . Combining agent act different site viral replication may improve HIV inhibition produce effective sustain anti-HIV effect .</brief_summary>
	<brief_title>A Randomized Phase II Study Two Doses Interferon Alfa-2a ( IFN Alfa-2a ) Combination With Zidovudine ( AZT ) Dideoxycytidine ( ddC ) Versus AZT ddC Only Patients With HIV Infection Less Than 400 CD4 Cells/mm3</brief_title>
	<detailed_description>AZT ddC inhibit HIV act reverse transcriptase chain terminator , IFN alfa-2a inhibits translation viral protein . Combining agent act different site viral replication may improve HIV inhibition produce effective sustain anti-HIV effect . Patients randomly assign one three treatment arm receive AZT/ddC alone combine one two dos IFN alfa-2a . Treatment continue 12 month enrollment last patient . Patients follow 2 , 4 , 8 week every 8 week thereafter . Mean duration follow-up expect 13 month .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Zalcitabine</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Isoniazid &lt; grade 2 peripheral neuropathy ( patient also take 50 mg/day pyridoxine ) . Phenytoin &lt; grade 2 peripheral neuropathy . A 21day course adjuvant systemic corticosteroid therapy moderate severe Pneumocystis carinii pneumonia ( PCP ) . Chemoprophylaxis PCP , candidiasis , herpes simplex infection ( 1 g acyclovir daily ) , Mycobacterium tuberculosis . Patients must : HIV infection . CD4 count &lt; 400 cells/mm3 within 30 day prior study entry . NOTE : Minimal Kaposi 's sarcoma allow . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Active opportunistic infection require acute therapy . Need maintenance therapy cytomegalovirus infection , toxoplasmic encephalitis , mycobacterial infection . Malignancy ( minimal Kaposi 's sarcoma ) require therapy . Grade 2 bad peripheral neuropathy . Concurrent Medication : Excluded : Other antiretroviral drug , biologic response modifier , cytotoxic chemotherapy , investigational drug ( unless approve protocol chair ) . Recombinant erythropoietin , GCSF , GMCSF . Drugs cause peripheral neuropathy , e.g. , gold , hydralazine , nitrofurantoin , vincristine , cisplatin , disulfiram , diethyldithiocarbamate ( unless approve protocol chair ) . Concurrent Treatment : Excluded : Radiation therapy ( unless approve protocol chair ) . Patients follow prior condition exclude : History intolerance AZT 600 mg/day less . Unexplained temperature 38.5 degree C persist 14 day longer . Unexplained , chronic diarrhea define 3 stool per day persist 14 day longer . Prior Medication : Excluded : Acute therapy opportunistic infection within 14 day prior study entry . Prior ddC , ddI , IFN alfa2a . Active substance abuse .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Zalcitabine</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Zidovudine</keyword>
	<keyword>Interferon-alpha</keyword>
</DOC>